EU and US could reach trade deal this weekend - Reuters
On Wednesday, UBS analyst Thomas Wadewitz revised the price target for FedEx (NYSE:FDX) shares, reducing it to $311 from the previous target of $331. Despite this change, Wadewitz has upheld a Buy rating for the company’s stock. Currently trading at $219.76, InvestingPro analysis suggests FedEx is undervalued, with additional metrics and insights available in the comprehensive Pro Research Report.
In his statement, Wadewitz pointed out that the environment for FedEx in the fourth quarter of fiscal year 2025 was likely more unstable and somewhat weaker than earlier projected, particularly in their international segment. This observation was in contrast to the company’s expectations set during the third-quarter earnings call in March. Despite recent challenges, FedEx maintains strong fundamentals with a Financial Health Score of ’FAIR’ according to InvestingPro metrics, and has demonstrated commitment to shareholder returns through aggressive share buybacks.
FedEx’s financial performance, especially in margins and earnings per share (EPS), is often significantly affected by fluctuations in demand. This sensitivity has prompted UBS to adjust its fourth-quarter fiscal year 2025 EPS estimate for FedEx downward, from $6.22 per share to $5.80 per share. The new estimate sits below the consensus estimate of $6.01 per share. The company maintains a solid track record of profitability, with a current P/E ratio of 13.64x and has consistently paid dividends for 24 consecutive years.
The adjustment reflects concerns about the international business climate that FedEx faces, which appears to be more challenging than the company anticipated. These challenges have the potential to influence the company’s earnings, as international operations are a key component of FedEx’s business model.
While the reduction in the EPS estimate indicates a cautious stance on FedEx’s short-term earnings potential, the maintained Buy rating suggests a continued positive long-term outlook on the stock by UBS. This rating implies that, despite near-term headwinds, UBS analysts still see value in FedEx shares for investors.
In other recent news, FedEx has achieved a significant milestone by earning the Center of Excellence for Independent (LON:IOG) Validators (CEIV) Pharma Certification for its global ground handling operations. This certification from the International Air Transport Association (IATA) highlights FedEx’s adherence to stringent industry standards for handling pharmaceutical products. Over 90% of FedEx’s healthcare volume is now processed through CEIV Pharma-certified facilities, enhancing its capabilities in pharmaceutical logistics. Additionally, FedEx is preparing for a major organizational change, with John Smith set to become President and CEO of FedEx Freight. This move is part of a broader strategy to spin off the FedEx Freight division by June 2026, with R. Brad Martin taking on the role of chairman for the new entity. Analyst opinions vary, with UBS maintaining a Buy rating and a $331 price target, citing Smith’s extensive experience as a positive factor. Conversely, BMO Capital Markets has lowered its price target for FedEx to $260 from $275, maintaining a Market Perform rating due to current challenges in the business-to-business freight market and broader economic uncertainties. These developments reflect FedEx’s ongoing efforts to adapt and grow in a complex economic environment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.